87 related articles for article (PubMed ID: 11522040)
1. An ideal biological marker of Alzheimer's disease: dream or reality?
Rípová D; Strunecká A
Physiol Res; 2001; 50(2):119-29. PubMed ID: 11522040
[TBL] [Abstract][Full Text] [Related]
2. Biological markers in Alzheimer's disease.
Grundke-Iqbal I; Rolkova G; Konstekova E; Iqbal K
Bratisl Lek Listy; 2006; 107(9-10):359-65. PubMed ID: 17262988
[TBL] [Abstract][Full Text] [Related]
3. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
Prvulovic D; Hampel H
Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
[TBL] [Abstract][Full Text] [Related]
4. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
6. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
[TBL] [Abstract][Full Text] [Related]
8. Biochemical Markers in Alzheimer's Disease.
Rabbito A; Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183332
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
11. Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease.
Lehmann S; Delaby C; Paquet C; Gabelle A
Clin Chem Lab Med; 2015 Jul; 53(8):e175-7. PubMed ID: 25870963
[No Abstract] [Full Text] [Related]
12. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
14. [Biomarker of dementia: clinical and preclinical diagnosis].
Shoji M
Nihon Rinsho; 2012 May; 70(5):857-63. PubMed ID: 22620013
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
16. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
19. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
